Effects of post-treatment systolic blood pressure on adverse outcomes in hypertensive population with comorbidity

The effect of hypertension on cardiovascular disease is increasingly evident, but the effect of hypertension with chronic medical conditions on adverse outcomes is less clear. To explore the minimum threshold range of target systolic blood pressure (SBP) in hypertensive population with comorbidities. A total of 11,388 hypertensive participants with comorbidities in the Kailuan cohort were selected. Propensity score matching (PSM) was also conducted among the 27,541 participants who suffered from hypertension without comorbidities and had received a physical examination in the same period. Finally, totaling 22,546 participants. After a follow-up of more than 7 years, the occurrence rate of CVD events in hypertensive participants with comorbidities was the minimum in the 110 ≤ SBP < 120 mm Hg group; the occurrence rate of CVD events in hypertensive participants without comorbidities was the minimum in the SBP < 110 mm Hg group; the all-cause mortality in participants with comorbidities and without comorbidities were the minimum in the 120 ≤ SBP < 130 mm Hg group. The results of the time-dependent Cox model and death competition risk model used in the two groups were consistent with those of the master model. The ideal post-treatment SBP in participants with comorbidities should be individualized. If the patient has a short life expectancy, his/her post-treatment SBP should be kept at 120 to 130 mm Hg. If the patient has a long life expectancy, his/her post-treatment SBP should be kept at 110 to 120 mm Hg.